Clofazimine
- Generic Name
- Clofazimine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H22Cl2N4
- CAS Number
- 2030-63-9
- Unique Ingredient Identifier
- D959AE5USF
- Background
Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as dapsone, for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although ...
- Indication
Clofazimine is indicated for the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. To prevent the development of drug resistance, it should be used only in combination with other antimycobacterial leprosy treatments.
- Associated Conditions
- Lepromatous Leprosy
- Associated Therapies
- -
Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Conditions
- Interventions
- Drug: darunavir/ritonavir dosage #1Drug: TAF w/cobicistatDrug: TAF w/cobicistat or ritonavirDrug: tenofovir alafenamide fumarate (TAF)Drug: elvitegravir/cobicistatDrug: darunavir/cobicistatDrug: atazanavir/cobicistatDrug: lopinavir/ritonavir dosage #1Drug: atazanavir/ritonavir/tenofovir dosage #1Drug: lopinavir/ritonavir dosage #2Drug: indinavir/ritonavir dosage #1Drug: fosamprenavir/ritonavirDrug: atazanavir/ritonavir dosage #1Drug: didanosine delayed release (Videx® EC)Drug: emtricitabineDrug: nelfinavir dosage #1Drug: tipranavir/ritonavirDrug: etravirineDrug: darunavir/ritonavir dosage #4Drug: indinavir/ritonavir dosage #2Drug: rilpivirineDrug: ethambutolDrug: efavirenzDrug: raltegravirDrug: dolutegravirDrug: kanamycinDrug: nevirapineDrug: amprenavirDrug: abacavirDrug: tenofovirDrug: maravirocDrug: darunavir/ritonavir dosage #2Drug: lopinavir/ritonavir dosage #3Drug: lopinavir/ritonavir dosage #4Drug: tenofovir/atazanavir/ritonavir dosage #2Drug: atazanavir/ritonavir dosage #2Drug: nelfinavir dosage #2Drug: rifampicinDrug: amikacinDrug: darunavir/ritonavir dosage #3Drug: etonogestrel implantDrug: capreomycinDrug: ethinyl estradiolDrug: isoniazidDrug: moxifloxacinDrug: levoflaxacinDrug: pyrazinamideDrug: ofloxacinDrug: ethionamide/prothionamideDrug: terizidone/cycloserineDrug: para-aminosalicylic acid (PAS)Drug: high dose INHDrug: bedaquilineDrug: clofazamineDrug: delamanidDrug: linezolidDrug: pretomanid
- First Posted Date
- 2002-08-01
- Last Posted Date
- 2022-07-22
- Target Recruit Count
- 1578
- Registration Number
- NCT00042289
- Locations
- 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇿🇦Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa
🇺🇸Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States
The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2015-01-16
- Lead Sponsor
- Abbott
- Registration Number
- NCT00002331
- Locations
- 🇺🇸
George Washington Univ Med Ctr, Washington, District of Columbia, United States
🇺🇸Dr Margaret Fischel, Miami, Florida, United States
🇺🇸Kaiser Permanente Med Ctr, San Francisco, California, United States
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of California, San Francisco
- Registration Number
- NCT00002058
- Locations
- 🇺🇸
Keith Med Group, Los Angeles, California, United States
🇺🇸San Francisco Gen Hosp, San Francisco, California, United States
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 525
- Registration Number
- NCT00000796
- Locations
- 🇺🇸
Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States
🇺🇸Cook County Hosp, Chicago, Illinois, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 90
- Registration Number
- NCT00000641
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States
🇺🇸Washington U CRS, Saint Louis, Missouri, United States
🇺🇸NY Univ. HIV/AIDS CRS, New York, New York, United States
Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 400
- Registration Number
- NCT00001047
- Locations
- 🇺🇸
Henry Ford Hosp, Detroit, Michigan, United States
🇺🇸Southern New Jersey AIDS Cln Trials / Dept of Med, Camden, New Jersey, United States
🇺🇸Richmond AIDS Consortium, Richmond, Virginia, United States
Study of Mycobacterial Infections
- First Posted Date
- 2001-06-29
- Last Posted Date
- 2024-12-20
- Target Recruit Count
- 1000
- Registration Number
- NCT00018044
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.